Aerosol Products

Powder Spray and Dry Powder Product Testing

Particle sizing, plume imaging, inhalation exposure, and stability support for powder sprays and dry powder products.

ARE Labs evaluates airborne powder behavior under defined use conditions to support formulation, package, exposure, and documentation decisions.

ISO 17025ISO 13320OSHA PEL / NIOSH RELICH Q1A (R2)Reviewed 2026-10-07
Request a quoteSubmit a sample

Testing powder spray and dry powder products

Powder spray and dry powder product testing links formulation, powder grade, applicator geometry, package state, and use condition to measured airborne behavior. ISO 13320 covers laser diffraction; aerodynamic sizing and plume imaging use separately defined protocols. OSHA and NIOSH limits provide occupational exposure context. FDA inhalation guidance and ICH references apply only to eligible drug products. Programs are usually scoped when:

  1. ISO 13320 laser diffraction compares powder grades and dispersion conditions; aerodynamic sizing separately addresses airborne size fractions and settling behavior.
  2. A defined imaging protocol examines clogging, sputtering, plume direction, and transient powder release; ICH Q9 provides risk-management context only for pharmaceutical programs.
  3. OSHA PEL or NIOSH REL comparisons use relevant workplace concentration and sampling inputs; consumer exposure requires a separately justified scenario and interpretation.
  4. Product-specific storage pulls track caking, agglomeration, cloud behavior, PSD drift, and package effects; ICH Q1A (R2) applies to eligible drug-product stability programs.
  5. FDA MDI / DPI guidance provides quality context when the product is an applicable inhalation drug product and needs aerodynamic sizing or emitted-output support.

Use this testing when powder output, airborne fraction, plume repeatability, caking, or exposure cannot be inferred from formulation specifications alone. Before samples arrive, the protocol defines powder handling, actuation, conditioning, sampling geometry, controls, and reporting endpoints.

Core testing menu for powder spray products

Powder spray programs usually combine particle sizing, transient imaging, exposure assessment, and storage pulls. The test set depends on the product claim, use scenario, and whether the powder is a consumer, industrial, or drug-like product.

Test method options

MethodStrengthsTradeoffAligned with
Dry powder particle size and respirable fraction screen
  • ISO 13320 laser diffraction reports optical size distributions; APS measurements separately report aerodynamic size distributions under a defined protocol.
  • Respirable fraction estimates require a stated measurement basis and sampling convention; applicable drug-product or occupational programs define their own interpretation limits.
Dispersion energy and humidity must be controlled before formulation comparisons are meaningful.
ISO 13320FDA MDI / DPI / nasalOSHA PEL / NIOSH REL
Transient powder plume imaging
  • Defined imaging documents clogging, sputtering, plume direction, and cloud breakup; ICH Q9 provides pharmaceutical risk context rather than an imaging method.
  • Frame-by-frame timing separates applicator effects from powder flowability and handling effects.
Imaging describes visible release behavior; pair with PSD or recovery when mass or exposure drives the claim.
ICH Q9
Inhalation exposure assessment
  • Chamber sampling and concentration-time data inform occupational exposure comparisons against applicable OSHA PEL or NIOSH REL benchmarks.
  • Use-scenario assumptions identify whether particle size, release rate, room volume, or duration drives margin of safety.
This supports exposure review; it does not replace complete toxicology, labeling, or product certification.
OSHA PEL / NIOSH REL
Stability and conditioning performance pulls
  • Product-specific storage tracks PSD, caking, plume and package changes; ICH Q1A (R2) applies only to eligible drug-product programs.
  • Trend tables support shelf-life, formulation, package, and storage-condition decisions.
Study duration follows the storage plan and pull schedule; endpoints should be locked before conditioning begins.
ICH Q1A (R2)
Inhalation drug-product output support
  • Cascade or aerodynamic sizing can support applicable inhalation drug products when FDA MDI / DPI quality expectations fit the product and endpoint.
  • Paired assay or tracer recovery connects emitted powder behavior to active-specific output where chemistry is required.
Broader CMC, clinical, biocompatibility, labeling, and full submission work remain outside this device page.
FDA MDI / DPI / nasal

Setup configurations

We design powder spray studies around powder state, package design, use mode, and the decision the data must support. Before runs begin, the protocol defines conditioning, handling, actuation, dispersion energy, sampling geometry, exposure scenario, analytical endpoint, controls, and replicate structure. These details let us interpret powder behavior against the product requirement or safety question.

Powder and package state

Powder grade, moisture history, fill level, package model, applicator geometry, nozzle state, storage age, and handling instructions documented per condition.

Flow & actuation profiles

Squeeze, pump, airflow, gravity-feed, or custom actuation with force, duration, orientation, discharge count, and rest interval defined by protocol.

Sampling geometry

Chambers, mannequins, breathing-zone probes, filters, impactors, particle counters, or imaging views selected for the intended use scenario.

Environmental controls

Temperature, RH, preconditioning, static-control notes, background aerosol, and post-storage handling recorded when powder flow or agglomeration may shift.

Sample numbers

Product count, powder lots, replicate runs, conditioning pulls, blanks, and controls are sized during protocol development from variability and endpoint sensitivity.

Quality frame for dry powder testing

Powder spray studies use an accredited laboratory quality framework, with separate aligned references for sizing, exposure, and stability. The same distinctions appear in the hero accreditation row.

  • ISO 17025AccreditedLaboratory competence, traceability, method control, and uncertainty contributors.
  • ISO 13320AlignedLaser diffraction principles for dry powder particle sizing.
  • OSHA PEL / NIOSH RELAlignedExposure benchmarks for inhalation assessment where applicable.
  • ICH Q1A (R2)AlignedDrug-product stability context; consumer-powder storage follows a separately defined protocol.

Key data outputs & reporting

The datasets link powder state and applicator setup to measured airborne behavior for each endpoint. Reports can support formulation screening, package comparison, inhalation exposure review, complaint investigation, stability trending, or regulatory documentation. For studies that include storage drift, exposure modeling, or comparator interpretation, extended deliverables provide the relevant pull-point and scenario context so the results can be read alongside the measured endpoints.

Primary outputs

  • PSD curves, Dv10/Dv50/Dv90 where applicable, aerodynamic fractions, respirable fraction estimates, and concentration-time profiles.
  • High-speed image sequences, discharge timing, visible clogging observations, plume direction, cloud duration, and setup photos.
  • Recovered powder mass, active or tracer recovery, chamber concentration by location, exposure-model inputs, and margin-of-safety tables.
  • Storage pull-point comparisons for caking, agglomeration, PSD drift, emitted behavior, package observations, and assay or tracer recovery.

Deliverables

#FormatContents
01PDF reportProtocol, setup, controls, deviations, endpoint tables, and interpretation limits.
02CSV / XLSX datasetsPSD, exposure, imaging, recovery, and stability trend tables.
03Images / videoHigh-speed frames, plume sequences, setup photos, and annotated observations.
Extended deliverables · multi-arm comparability · stability · predicate studies
  • Exposure appendix — Scenario assumptions, concentration-time data, particle sizing, benchmark inputs, and sensitivity outputs.
  • Stability trend pack — Pull-point tables and figures for PSD, caking, plume behavior, package observations, and recovery results.
  • Comparator summary — Side-by-side formulation, powder grade, applicator, or package comparisons with endpoint-specific limits.

QA / QC & data integrity

Each powder spray study has a QA/QC plan matched to its endpoints and powder handling risks. Controls run alongside collection to keep particle, imaging, exposure, recovery, and trend data traceable from sample receipt through the final report. Study records document deviations, exclusions, and conditioning events.

Device-off backgrounds, chamber blanks, blank fixtures, reference powders, or no-actuation controls selected by endpoint.

Flow meters, balances, particle instruments, imaging scales, environmental sensors, and analytical instruments checked or calibrated before use.

Powder conditioning, humidity, discharge timing, orientation, sampling location, dispersion settings, and recovery procedure recorded per run.

Recovery, carryover, blank correction, matrix effects, and static-loss checks included when chemistry or tracer endpoints require them.

Chain of custody covers powder lots, packages, filters, impactor stages, extracts, raw files, images, calculations, and report tables.

Why ARE Labs

ARE Labs connects technical topics to practical study design, method selection, controlled aerosol work, and reportable evidence without turning technical pages into sales pages.

Reviewed byJamie Balarashti (25 yrs - cascade & inhalation methods) - Weston Schaper (7 yrs - real-time sizing & nanoparticle work)
QualityDocumented study records
900+Studies Performed
17+Years in operation
300+Clients supported

Common questions

Powder spray, dry powder product, formulation, and package teams often need to decide which endpoints to combine and how powder handling will be controlled. The answers below also cover sample needs, deliverables, and the limits of defined testing. Most programs require at least one product-specific decision about conditioning, actuation, sampling geometry, or exposure assumptions before the study can be scoped.

Q.Which powder spray test should I start with?
A.Start with the decision. PSD describes particle size; respirable fraction estimates depend on the measurement basis and sampling convention. Imaging shows release behavior, inhalation assessment evaluates exposure, and stability testing tracks storage drift.
Q.How is powder handling controlled?
A.We define conditioning, humidity, handling steps, actuation, orientation, discharge count, and sampling geometry in the protocol. Those controls matter because powder flowability and agglomeration can change quickly.
Q.Can ARE Labs support drug-like dry powder products?
A.Yes, within a defined scope covering aerosol measurements, sizing, emitted powder behavior, and analytical support. Broader CMC, clinical, labeling, biocompatibility, and full submission work require a separate scope.
Q.What affects sample count and timeline?
A.Sample needs depend on powder lots, product configurations, conditioning states, endpoints, exposure scenarios, assays, and replicates. Stability programs also follow the storage pull schedule.
Q.What data will we receive?
A.Deliverables can include a PDF report, CSV/XLSX datasets, PSD curves, concentration time series, high-speed images, exposure calculations, recovery data, trend plots, and QA/QC records.

Standards & guidance

Powder spray and dry powder product programs are usually fit-for-purpose: the product's intended use determines which references apply. ARE Labs selects references for each measurement endpoint and reports whether the method is accredited, aligned, or conformant where applicable. The rows below list the standards and guidance clusters most often used for particle sizing, imaging investigations, inhalation exposure, and storage-trend work.

QA & Regulatory - Accredited

ISO 17025

Laboratory competence, calibration traceability, method control, and reporting qualityView standard ->Particle & Aerosol Measurement - Aligned

ISO 13320

Laser diffraction particle sizing principles for dry powder and powder-cloud spectraView standard ->Inhalation & Drug Delivery - Aligned

FDA MDI / DPI / nasal

Applicable inhalation drug-product quality context for dry powder output and aerodynamic sizingView standard ->QA & Regulatory - Aligned

ICH Q9

Pharmaceutical quality-risk context for investigations; not a powder imaging test methodView standard ->Exposure & Safety - Aligned

OSHA PEL / NIOSH REL

Exposure benchmarks used for inhalation-risk support and scenario comparisonsView standard ->Stability - Aligned

ICH Q1A (R2)

Eligible drug-product stability context; product-specific protocols govern consumer-powder storageView standard ->

Related testing services

Test

Particle Size Distribution (PSD) Testing

Quantifies powder particle size, aerodynamic fraction, and respirable fraction for formulation, applicator, exposure, and storage comparisons.Read more ->Test

High-Speed Imaging & Velocimetry

Documents transient powder release, clogging, sputtering, plume direction, and applicator-driven timing changes.Read more ->Test

Inhalation Risk Assessment

Connects measured powder PSD and chamber concentration data to scenario exposure and margin-of-safety review.Read more ->Test

Stability and Accelerated Aging

Tracks caking, agglomeration, PSD drift, package effects, emitted behavior, and recovery across storage pulls.Read more ->